Evidence map›Paper›PMID 31690955›Full record

ReviewCancer immunology, immunotherapy : CII2019

Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope.

Evelina Martinenaite, Shamaila Munir Ahmad, Simone Kloch Bendtsen, Mia Aaboe Jørgensen, Stine Emilie Weis-Banke, Inge Marie Svane, Mads Hald Andersen

Abstract readReview
In one paragraph

Review in Cancer immunology, immunotherapy : CII, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Integrating Metabolic Modulation and Nanomedicine for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  6. The roles of arginases and arginine in immunity.Nature reviews. Immunology · 2025
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Tumor microenvironment antigens.Seminars in immunopathology · 2023
    Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Evelina MartinenaiteNational Center for Cancer Immune Therapy (CCIT-dk), Copenhagen University Hospital Herlev, Borgmester Ib Juuls Vej 25C, 2730, Herlev, Denmark.ORCID http://orcid.org/0000-0002-4690-8722
Shamaila Munir AhmadNational Center for Cancer Immune Therapy (CCIT-dk), Copenhagen University Hospital Herlev, Borgmester Ib Juuls Vej 25C, 2730, Herlev, Denmark.
Simone Kloch BendtsenNational Center for Cancer Immune Therapy (CCIT-dk), Copenhagen University Hospital Herlev, Borgmester Ib Juuls Vej 25C, 2730, Herlev, Denmark.
Mia Aaboe JørgensenNational Center for Cancer Immune Therapy (CCIT-dk), Copenhagen University Hospital Herlev, Borgmester Ib Juuls Vej 25C, 2730, Herlev, Denmark.
Stine Emilie Weis-BankeNational Center for Cancer Immune Therapy (CCIT-dk), Copenhagen University Hospital Herlev, Borgmester Ib Juuls Vej 25C, 2730, Herlev, Denmark.
Inge Marie SvaneNational Center for Cancer Immune Therapy (CCIT-dk), Copenhagen University Hospital Herlev, Borgmester Ib Juuls Vej 25C, 2730, Herlev, Denmark.
Mads Hald AndersenNational Center for Cancer Immune Therapy (CCIT-dk), Copenhagen University Hospital Herlev, Borgmester Ib Juuls Vej 25C, 2730, Herlev, Denmark. mads.hald.andersen@regionh.dk.ORCID http://orcid.org/0000-0002-2914-9605

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

L-arginine depletion by regulatory cells and cancer cells expressing arginase-1 (Arg-1) is a vital contributor to the immunosuppressive tumor microenvironment in patients with cancer. We have recently described the existence of pro-inflammatory effector T cells that recognize Arg-1. Hence, Arg-1-specific self-reactive T cells are a naturally occurring part of the memory T-cell repertoire of the human immune system. Here, we further characterize a highly immunogenic epitope from Arg-1. We describe frequent T-cell-based immune responses against this epitope in patients with cancer, as well as in healthy donors. Furthermore, we show that Arg-1-specific T cells expand in response to the T

Indexed as

AnimalsArginaseCancer VaccinesEpitopes, T-LymphocyteHumansNeoplasmsT-LymphocytesTumor MicroenvironmentVaccinationArginaseCancer VaccinesEpitopes, T-LymphocyteAnti-regulatory T cellsArginaseImmune-modulating vaccinesIO112PIVAC 18

Identifiers

PMID31690955
PMCPMC11028269

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.